$WAT

KUEBLER CHRISTOPHER A sold $1.4M of WAT

KUEBLER CHRISTOPHER A sold 3,626 shares of WATERS CORP /DE/ (WAT) at $397.94 ($1.44M total) on 2026-08-06.

Original reporting
SEC EDGAR · KUEBLER CHRISTOPHER A
Published Aug 7, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$WAT
Neutral
low confidence
Mentioned
$WAT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WATNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price, and post-transaction holdings. It may slightly affect sentiment, but it does not introduce new operational or financial information about Waters.

02

Market read

Traders may note insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The filing does not state a 10b5-1 plan, but it also provides no rationale for the sale, so interpreting it as bearish on fundamentals is speculative.

Relevance 6/10Novelty 3/10Timing: filed after-hours on Aug 7, transaction dated Aug 6

Background

The article is an SEC Form 4 insider transaction disclosure for Waters Corp, reported by director Christopher A Kuebler.

Company-level read

Ticker impact

$WATNeutralLow confidence
Context

Waters Corp director Christopher A Kuebler sold 3,626 shares in an open-market transaction valued at about $1.44M, per Form 4 filed Aug 7.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless follow-on selling accelerates.

Evidence & confidence

This is a routine Form 4 insider sale with no 10b5-1 plan stated and no accompanying company-specific news (earnings, guidance, deals, or regulatory actions).

Market effects

No clear sector read-through from a single director sale filing.

None indicated.

None indicated.

Counterpoint

Insider sales are often planned for diversification or liquidity needs; without evidence of broader selling, the signal may be overstated.

Key entities

  • WATERS CORP /DE/

    Waters Corp, the company whose director insider sale is disclosed in the Form 4.

  • KUEBLER CHRISTOPHER A

    Director who sold 3,626 shares at $397.94/share, totaling about $1.44M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BRKRHighAI 8/10

Research Tools & Consumables Stocks Q2 Highlights: Bruker (NASDAQ:BRKR)

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.

$WATHighAI 8/10

Is Wall Street Bullish or Bearish on Waters Corporation Stock?

Waters Corporation (WAT), a $40.7B life sciences and diagnostics company, reported Q2 2026 adjusted EPS of $3.05 and revenue of $1.65B, exceeding expectations. The stock has risen 43% over 52 weeks, outperforming the S&P 500. Analysts expect 10.9% EPS growth for 2026, with a consensus 'Moderate Buy' rating and a mean price target of $438.43.

$WATMed

WAT Upgraded by Piper Sandler -- Price Target Raised to $480

Piper Sandler upgraded Waters Corporation (WAT) to Overweight, raising its price target to $480 from $400. The company's stock is currently trading at $423.22, slightly above its GF Value™ of $411.65, indicating a 2.8% overvaluation. Waters Corporation has a GF Score™ of 95/100, reflecting strong growth and momentum but moderate financial strength. Insider activity shows recent selling of $1,442,930 worth of shares.

$WATHighAI 9/10

Waters (WAT) Q2 2026 Earnings Call Transcript

Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.

$WATMedAI 8/10

Waters Q2 Earnings Call Highlights

Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.